This study represents the first comprehensive evaluation we know of the clinical utility of the tumor markers CEA, CA19-9, and CA125 in more than a thousand patients with appendiceal adenocarcinoma, establishing that each of the 3 are biomarkers associated with outcomes. Here, MUC16 is linked to appendix adenocarcinoma.